Tilray Medical, a global leader in medical cannabis research, cultivation, production, products and distribution and a division of Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), today announced its participation in Cannabis Europa London 2026, one of Europe’s leading forums for medical cannabis policy, science, and regulation.
Cannabis Europa London 2026 will bring together policymakers, healthcare professionals, researchers, and industry leaders to discuss the future of medical cannabis regulation, innovation, and public health policy in Europe.
José Tempero, Director of International Medical Affairs at Tilray Medical, will participate in a featured panel discussion titled, “Evidence First: Designing Public Policy Through Data and Trials,” taking place on May 26 at 12:00 p.m., at The Barbican in London.
The panel will explore how European pilot programmes, clinical research, and real-world evidence are helping shape responsible, evidence-based cannabis policy frameworks across Europe. Discussions will include the role of clinical trials, public health data, patient outcomes, and scalable regulatory approaches.
José Tempero, Director of International Medical Affairs, Tilray Medical, said: “As the European medical cannabis landscape continues to evolve, science, research, and clinical evidence remain critical to building responsible healthcare frameworks and improving patient access. We look forward to contributing to these important conversations alongside policymakers, researchers, and healthcare leaders from across Europe.”
Stephen Murphy, Founder, Cannabis Europa & Prohibition Partners, said: “Tilray’s continued engagement at Cannabis Europa reflects the importance of bringing together policymakers, clinicians, regulators, investors, and industry leaders to shape the future of medical cannabis in Europe. As access expands across international markets, meaningful progress will depend on open collaboration, credible scientific dialogue, and long-term stakeholder engagement. Cannabis Europa exists to provide that platform and to help ensure the next phase of industry growth is built on evidence, patient outcomes, and responsible regulation.”
Tilray Medical and Lyphe Clinic, Tilray Medical’s U.K.-based medical cannabis clinic and digital patient platform, will co-host the official Cannabis Europa London 2026 afterparty for registered attendees. Lyphe supports patient consultations, prescriptions, education, and access to medical cannabis treatments as part of Tilray Medical’s broader international healthcare platform focused on advancing patient-centric medical cannabis care across Europe. Through Tilray Medical’s integrated international platform, the Company continues to support healthcare professionals, expand patient access pathways, and advance the responsible adoption of pharmaceutical-grade medical cannabis across key international markets.
With operations spanning more than 20 highly regulated international markets, Tilray Medical has built one of the industry’s most established global medical cannabis platforms, supported by pharmaceutical-quality cultivation, manufacturing, and distribution capabilities, as well as deep regulatory expertise developed through years of engagement with healthcare authorities worldwide. Having supported hundreds of thousands of patients globally through a broad portfolio of cannabinoid-based products, including CBD and THC formulations across multiple delivery formats, Tilray Medical is well-positioned to continue advancing high standards of quality, compliance, and patient care across international markets. Through continued investment in clinical education, product stewardship, and compliant supply infrastructure, Tilray Medical remains focused on advancing safe, reliable, and consistent patient access worldwide.
The post Tilray Medical Brings Global Medical Cannabis Expertise to Cannabis Europa London 2026 appeared first on Business of Cannabis.
Continue reading...
Cannabis Europa London 2026 will bring together policymakers, healthcare professionals, researchers, and industry leaders to discuss the future of medical cannabis regulation, innovation, and public health policy in Europe.
José Tempero, Director of International Medical Affairs at Tilray Medical, will participate in a featured panel discussion titled, “Evidence First: Designing Public Policy Through Data and Trials,” taking place on May 26 at 12:00 p.m., at The Barbican in London.
The panel will explore how European pilot programmes, clinical research, and real-world evidence are helping shape responsible, evidence-based cannabis policy frameworks across Europe. Discussions will include the role of clinical trials, public health data, patient outcomes, and scalable regulatory approaches.
José Tempero, Director of International Medical Affairs, Tilray Medical, said: “As the European medical cannabis landscape continues to evolve, science, research, and clinical evidence remain critical to building responsible healthcare frameworks and improving patient access. We look forward to contributing to these important conversations alongside policymakers, researchers, and healthcare leaders from across Europe.”
Stephen Murphy, Founder, Cannabis Europa & Prohibition Partners, said: “Tilray’s continued engagement at Cannabis Europa reflects the importance of bringing together policymakers, clinicians, regulators, investors, and industry leaders to shape the future of medical cannabis in Europe. As access expands across international markets, meaningful progress will depend on open collaboration, credible scientific dialogue, and long-term stakeholder engagement. Cannabis Europa exists to provide that platform and to help ensure the next phase of industry growth is built on evidence, patient outcomes, and responsible regulation.”
Tilray Medical and Lyphe Clinic, Tilray Medical’s U.K.-based medical cannabis clinic and digital patient platform, will co-host the official Cannabis Europa London 2026 afterparty for registered attendees. Lyphe supports patient consultations, prescriptions, education, and access to medical cannabis treatments as part of Tilray Medical’s broader international healthcare platform focused on advancing patient-centric medical cannabis care across Europe. Through Tilray Medical’s integrated international platform, the Company continues to support healthcare professionals, expand patient access pathways, and advance the responsible adoption of pharmaceutical-grade medical cannabis across key international markets.
With operations spanning more than 20 highly regulated international markets, Tilray Medical has built one of the industry’s most established global medical cannabis platforms, supported by pharmaceutical-quality cultivation, manufacturing, and distribution capabilities, as well as deep regulatory expertise developed through years of engagement with healthcare authorities worldwide. Having supported hundreds of thousands of patients globally through a broad portfolio of cannabinoid-based products, including CBD and THC formulations across multiple delivery formats, Tilray Medical is well-positioned to continue advancing high standards of quality, compliance, and patient care across international markets. Through continued investment in clinical education, product stewardship, and compliant supply infrastructure, Tilray Medical remains focused on advancing safe, reliable, and consistent patient access worldwide.
The post Tilray Medical Brings Global Medical Cannabis Expertise to Cannabis Europa London 2026 appeared first on Business of Cannabis.
Continue reading...
